Medical Cannabis for Metabolic Syndrome — Switzerland 2026
THCV and CBD modulate insulin sensitivity and lipid metabolism. Add-on in metabolic syndrome — members save.
~1.5M Swiss have metabolic syndrome (obesity + insulin resistance + dyslipidemia). Standard: metformin, statins, lifestyle. THCV acts as CB1 antagonist — appetite-suppressing, insulin-sensitizing (Jadoon 2016 RCT). CBD reduces inflammation and steatosis markers. Add-on. Members: 50 CHF instead of 190.
What the studies show
Jadoon 2016 (Diabetes Care RCT, n=62): THCV 5 mg/day over 13 weeks lowers fasting glucose and improves β-cell function in T2D.
Meta-analysis 2020: cannabis consumers have lower obesity prevalence (paradoxical effect via CB1 down-regulation).
Preparations & dosing
THCV extract 5–10 mg mornings — appetite suppression, no THC psychoactivity.
Full-spectrum CBD 50 mg twice daily — anti-inflammatory, improves liver enzymes.
Save as a CannabisClub member
Endocrinology/obesity cannabis consultation: 190–280 CHF. Members: 50 CHF flat. Registration free.
FAQ
Does cannabis replace my metformin?
No. Metformin remains standard — THCV/CBD are add-on to lifestyle.
What does membership save?
50 CHF instead of 190 CHF per consultation. Registration free.
Does insurance cover it?
No — metabolic syndrome is not a standard cannabis indication. Out of pocket.
Cannabis for Metabolic Syndrome & Obesity — CBD/THCV Switzerland 2026 (Members 50 CHF)